DLA Piper represents Neothetics in initial public offering
DLA Piper advised Neothetics, a clinical-stage speciality pharmaceutical company developing therapeutics for the aesthetic market, in the pricing of its initial public offering (IPO) of 4,650,000 shares of its common stock at a public offering price of $14 (£9) per share. The San Diego-based DLA Piper team representing Neothetics was led by partners Michael Kagnoff […]